Biotech Analyst Yee and Dr. Armen Moughamian, (Alzheimer’s Doctor in California) and Eric Katz, CMS expert, discuss the early days of Biogen (BIIB) Legembi launch and the hurdles still present post CMS reimbursement, the market dynamics with Eli Lilly’s Donanemab which will be on the market by YE:23 on an Analyst/Industry conference call to be held on September 20 at 11 am. Webcast Link
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on BIIB:
